

CPA/671-16478

RECEIVED

OCT 23 2000

CHECK BOX, if applicable

TECH CENTER 1600/2900

10/24/00

**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL**

Submit an original, and a duplicate for fee processing.
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

☐ DUPLICATE

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No. of Prior Application	A-451G
	First Named Inventor	Boyle, William J.
	Examiner Name	Turner, S.
	Group / Art Unit	1647
	Express Mail Label No.	EL360688038US

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 09/211,315, filed on December 14, 1998, entitled Osteoprotegerin Binding Proteins

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000 a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office (Apr. 11, 2000).

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 153(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. ☐ Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior nonprovisional application.
2. ☐ A preliminary amendment is enclosed.
3. ☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4).
a. ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:
- b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent is enclosed.
5. ☒ Supplemental Information Disclosure Statement (IDS) is enclosed:
a. ☒ PTO-1449
b. ☒ Copies of IDS Citations

10/20/2000 AUNDALF1 00000082 010519 09211115

01 FC:131	710.00 CH
02 FC:102	640.00 CH
03 FC:103	370.00 CH
04 FC:104	270.00 CH

RECEIVED

CLAIMS AS FILED

OCT 23 2000

For	Number Filed		Number Extra	Rate	Fee
Total Claims	41	- 20 =	21	x \$18.00 =	\$ 378.00
Independent Claims	11	- 3 =	8	x \$80.00 =	\$640.00
MULTIPLE DEPENDENT CLAIMS (if applicable)			5	+ \$270.00 =	270.00
Basic Fee				=	\$710.00
Total Filing Fee:					\$1998.00

6. ☒ Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.
7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 01-0519 throughout the prosecution of this application:
- a. ☒ Fees required under 37 CFR 1.16.
- b. ☒ Fees required under 37 CFR 1.17.
- c. ☐ Fees required under 37 CFR 1.18.
8. ☐ A check in the amount of \$_____ is enclosed.
9. ☒ New Attorney Docket Number, if desired A-451J
[Prior application Attorney Docket Number will carry over to this CPA unless a new Attorney Docket Number has been provided herein.]
10. a. ☐ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)
- b. ☒ Return Receipt Postcard (Should be specifically itemized. See MPEP 503.)
11. ☐ Other: _____

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.


12. NEW CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

or ☒ New correspondence address below

NAME	U.S. Patent Operations/RBW					
	M/S 27-4-A, Department 4300					
ADDRESS	AMGEN INC.					
	One Amgen Center Drive					
CITY	Thousand Oaks	STATE	CA	ZIP CODE	91320-1799	
COUNTRY	US	TELEPHONE	805-447-2425	FAX	805-499-8011	

11. SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED

NAME (Print/Type)	Robert B. Winter
SIGNATURE	
REGISTRATION NO. (Attorney/Agent)	34,458
DATE	October 18, 2000



PATENT APPLICATION

RECEIVED #6

OCT 23 2000

TECH CENTER 1600/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle, William J.

Serial No.: 09/211,315

Group Art Unit No.: 1647

Filed: December 14, 1998

Examiner: Turner, S.

For: Osteoprotegerin Binding Proteins

Docket No.: A-451J

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicant submits a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: October 18, 2000

Please send all future correspondence to:

U.S. Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360688038US

Date of Deposit: October 18, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

S. L. ST. ANDREW
Printed Name

S. L. St. Andrew
Signature